Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19

Overview of attention for article published in JAMA: Journal of the American Medical Association, December 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 16 news outlets
blogs: 3 blogs
twitter: 153 X users

facebook: 1 Facebook page
reddit: 1 Redditor
podcasts: 1 podcast

Readers on

mendeley: 30 Mendeley

So far, Altmetric has seen 19 news stories from 16 outlets.

Fluvoxamin kann die Dauer der COVID-19-Symptome bei ambulanten Patienten mit leichtem bis mittelschwerem Verlauf nicht verkürzen

Germanic.News, 09 Dec 2024

#Fluvoxamin #kann #die #Dauer #der #COVID19Symptome #bei #ambulanten #Patienten #mit #leichtem #bis #mittelschwerem #Verlauf #nic…

フルボキサミンは軽度から中等度の外来患者の新型コロナウイルス感染症の症状持続期間を短縮できない

Nipponese.news, 08 Dec 2024

新型コロナウイルス感染症の治療における再利用された医薬品の有効性は、依然として重要な研究分野です。新しい分析では、抗炎症作用のある抗うつ薬であるフルボキサミン（Luvox）を高用量摂取しても、プラセボと比較して持続的回復までの時間を大幅に短縮しないことが判明…

Fluvoxamine Fails to Shorten COVID-19 Symptom Duration in Mild to Moderate Outpatients

AJMC, 08 Dec 2024

The effectiveness of repurposed medications for treating COVID-19 remains a critical area of investigation.

Fluvoxamine Does Not Shorten Duration of COVID-19 Symptoms

Endocrinology Advisor, 30 Nov 2023

No deaths were reported, but 35 participants reported health care use events, including 14 in the fluvoxamine group and 21 in…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 15 additional news stories.